Don’t let misinformation derail the trachoma elimination programme

[...]data from a 1998-9 western Nepal trial were extrapolated to estimate effectiveness of mass treatment throughout sub-Saharan Africa and South East Asia. [...]costs were assigned for azithromycin purchase using a theoretical price. 2 Azithromycin for trachoma control is donated by the manufacture...

Full description

Saved in:
Bibliographic Details
Published in:BMJ (Online) 2012-04, Vol.344 (apr10 2), p.e2579; author reply e2588-e2579
Main Author: Solomon, Anthony W
Format: Article
Language:English
Subjects:
Chlamydia trachomatis
Cost control
False information
GDP
Gross Domestic Product
Health Priorities
Humans
Primary Prevention - standards
Trachoma
Wounds and Injuries - prevention & control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]data from a 1998-9 western Nepal trial were extrapolated to estimate effectiveness of mass treatment throughout sub-Saharan Africa and South East Asia. [...]costs were assigned for azithromycin purchase using a theoretical price. 2 Azithromycin for trachoma control is donated by the manufacturer. On the basis of analyses that are flawed on both sides of the cost effectiveness equation, Chisholm and colleagues concluded that saving a DALY with mass azithromycin treatment in trachoma endemic areas of sub-Saharan Africa or South East Asia costs more than the per capita gross domestic product of each region.
ISSN:0959-8138
1756-1833
1756-1833
DOI:10.1136/bmj.e2579